(iPr2N)2PO(CH2)2CN | 144485-60-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (iPr2N)2PO(CH2)2CN
• 英文别名: 3-[[Di(propan-2-yl)amino]-oxidophosphaniumyl]oxypropanenitrile；3-[[di(propan-2-yl)amino]-oxidophosphaniumyl]oxypropanenitrile
• CAS: 144485-60-9
• 化学式: C₉H₁₉N₂O₂P
• 分子量: 218.236
• InChiKey: WFOPHJRPISMLSE-UHFFFAOYSA-N

物化性质

• 沸点：
  314.3±44.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 (iPr2N)2PO(CH2)2CN 在 2H-tetrazole 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以50%的产率得到
  参考文献：
  名称：

  光応答性ヌクレオチドアナログ

  摘要：

  提供一种可用于核酸光反应技术的新型光反应性化合物。在核糖骨架中，选择来自天然和非天然核酸碱基以及这些经过修饰的修饰核酸碱基群中的一个核酸碱基的单价基连接到1位，并且通过单键或经由C1到C7的烷基连接到2位的氰基苯乙烯基与氰基苄咪唑结合的人工核苷酸和人工核酸。【选择图】无

  公开号：

  JP2021020883A
• 作为产物：
  描述：

  2-氰乙基N,N-二异丙基氯亚磷酰胺 在 水 、 N,N-二异丙基乙胺 作用下， 生成 (iPr2N)2PO(CH2)2CN
  参考文献：
  名称：

  焦磷酸键连接寡核苷酸的合成

  摘要：

  在本文中，我们重新审视了通过焦磷酸盐互连的寡核苷酸的合成方法，该方法依赖于磷酸二酰胺酐的反应性。我们发现这种由 Ahmadibeni 和 Parang (2007) 先前发表的方法在我们手中是不可复制的。我们通过我们独立开发的方法成功合成了三个焦磷酸互连的胸苷寡核苷酸，与他们文章中要求保护的结构相同。对新合成产品的光谱数据的评估使人们对 Ahmadibeni-Parang 方法的可行性产生了怀疑。因此，我们相信在这里报告了通过焦磷酸键互连的 DNA 寡聚体的首次成功合成。

  DOI：

  10.1002/ejoc.201500911

文献信息

• Oligomeric compounds for the modulation survivin expression
  申请人：Hansen Bo

  公开号：US20050014712A1

  公开（公告）日：2005-01-20

  Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

  提供针对survivin基因的寡核苷酸，用于调节survivin的表达。这些组合物包括寡核苷酸，特别是针对编码survivin的核酸的反义寡核苷酸。提供使用这些化合物调节survivin表达和治疗与survivin过度表达，表达突变survivin或两者都有关的疾病的方法。疾病的例子是癌症，如肺癌，乳腺癌，结肠癌，前列腺癌，胰腺癌，肝癌，甲状腺癌，肾癌，脑癌，睾丸癌，胃癌，肠道癌，脊髓癌，鼻窦癌，膀胱癌，泌尿道或卵巢癌。寡核苷酸可以由脱氧核糖核苷或核酸类似物组成，例如锁定核酸酸或两者的组合。
• Oligomeric compounds for the modulation of thioredoxin expression
  申请人：Santaris Pharma A/S

  公开号：US20040241717A1

  公开（公告）日：2004-12-02

  Oligonucleotides directed against the TRX gene are provided for modulating the expression of TRX. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the TRX. Methods of using these compounds for modulation of TRX expression and for the treatment of diseases associated with either overexpression of TRX, expression of mutated TRX or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

  提供针对TRX基因的寡核苷酸，用于调节TRX的表达。这些组合物包括寡核苷酸，特别是针对编码TRX的核酸的反义寡核苷酸。提供了使用这些化合物调节TRX表达和治疗与TRX过度表达、突变TRX表达或两者都相关的疾病的方法。疾病的例子包括肺癌、乳腺癌、结肠癌、前列腺癌、胰腺癌、肝癌、甲状腺癌、肾癌、脑癌、睾丸癌、胃癌、肠癌、脊髓癌、鼻窦癌、膀胱癌、泌尿道癌或卵巢癌等。这些寡核苷酸可以由脱氧核苷酸或核酸类似物组成，例如锁定核酸或二者的组合。
• Oligomeric compounds for the modulation of ras expression
  申请人：Santaris Pharma A/S

  公开号：US20040248840A1

  公开（公告）日：2004-12-09

  Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

  提供了针对Ha-ras基因的寡核苷酸，用于调节Ha-ras的表达。该组成物包括针对编码Ha-ras的核酸的寡核苷酸，特别是反义寡核苷酸。提供了使用这些化合物调节Ha-ras表达和治疗与Ha-ras过度表达、突变Ha-ras表达或两者都有关的疾病的方法。疾病的例子包括肺癌、乳腺癌、结肠癌、前列腺癌、胰腺癌、肝癌、甲状腺癌、肾癌、脑癌、睾丸癌、胃癌、肠癌、脊髓癌、鼻窦癌、膀胱癌、泌尿道癌或卵巢癌。寡核苷酸可以由脱氧核苷酸或核酸类似物组成，例如锁定核酸或两者的组合。
• Oligomeric compounds for the modulation ras expression
  申请人：Hansen Bo

  公开号：US20080188432A1

  公开（公告）日：2008-08-07

  Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

  本发明提供了针对Ha-ras基因的寡核苷酸，用于调节Ha-ras的表达。该组合物包括寡核苷酸，特别是针对编码Ha-ras的核酸的反义寡核苷酸。提供了使用这些化合物调节Ha-ras表达以及治疗与Ha-ras过度表达，突变Ha-ras表达或两者都有关的疾病的方法。疾病的例子是癌症，如肺癌、乳腺癌、结肠癌、前列腺癌、胰腺癌、肝癌、甲状腺癌、肾癌、脑癌、睾丸癌、胃癌、肠癌、脊髓、鼻窦、膀胱、泌尿道或卵巢癌。寡核苷酸可以由脱氧核苷酸或核酸类似物组成，例如锁定核酸或其组合。
• OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
  申请人：Hansen Jens Bo rode

  公开号：US20090318362A1

  公开（公告）日：2009-12-24

  Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

  本发明提供了针对survivin基因的寡核苷酸，用于调节survivin的表达。这些组合物包括寡核苷酸，特别是针对编码survivin的核酸的反义寡核苷酸。提供了使用这些化合物调节survivin表达并治疗与survivin过度表达、表达突变survivin或两者都有关的疾病的方法。例如，这些疾病包括肺癌、乳腺癌、结肠癌、前列腺癌、胰腺癌、肝癌、甲状腺癌、肾癌、脑癌、睾丸癌、胃癌、肠癌、脊髓癌、鼻窦癌、膀胱癌、泌尿道癌或卵巢癌等癌症。这些寡核苷酸可以由脱氧核苷酸或核酸类似物组成，例如锁定核酸或两者的组合。